Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Go back to Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer| ALKERMES (NASDAQ: ALKS) | Delayed: 45.93 -0.17 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.10 | 52 Week High | $80.71 | |||
| Open | $45.20 | 52 Week Low | $27.14 | |||
| Day High | $46.39 | P/E | 353.31 | |||
| Day Low | $44.63 | EPS | $0.13 | |||
| Volume | 494,985 | |||||
